| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.2146/AJHP110500 |
| P698 | PubMed publication ID | 23230035 |
| P2093 | author name string | Susan Jacob | |
| Jerika T Lam | |||
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System | Q27485441 | ||
| Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034) | Q27487769 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Global challenges in liver disease | Q33999114 | ||
| Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection | Q34735780 | ||
| Peginterferon and ribavirin for chronic hepatitis C. | Q36675912 | ||
| Protease and polymerase inhibitors for the treatment of hepatitis C. | Q37389936 | ||
| Boceprevir, an NS3 protease inhibitor of HCV. | Q37560264 | ||
| Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. | Q40322833 | ||
| Big Changes Are Coming in Hepatitis C | Q42579974 | ||
| Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial | Q42943536 | ||
| Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay | Q42981143 | ||
| In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms | Q42982898 | ||
| Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 | ||
| In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. | Q42994273 | ||
| Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia | Q42996604 | ||
| Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy | Q42999651 | ||
| Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor | Q43031532 | ||
| Characterization of resistance mutations against HCV ketoamide protease inhibitors | Q43047638 | ||
| Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients | Q43269846 | ||
| Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. | Q50578652 | ||
| The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice | Q84478793 | ||
| P433 | issue | 24 | |
| P921 | main subject | Hepatitis C virus | Q708693 |
| P304 | page(s) | 2135-2139 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | American Journal of Health-System Pharmacy | Q15754037 |
| P1476 | title | Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection | |
| P478 | volume | 69 |
Search more.